Patients with inflammatory bowel disease and GI cancers were more likely to get vaccinations such as flu shots after a consultation with a health care provider, according to a study published in Alimentary Pharmacology & Therapeutics. IBD and GI cancer patients have a high risk of contracting flu or pneumococcus, but the vaccination rate is
Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). A recent study finds that pretreatment α4β7 expression and α4β7 receptor saturation during maintenance therapy were identified as candidate biomarkers for vedolizumab response. This assay leads to promise that we will be able to identify good candidates for biologic therapies
